

Pharma Fail: Arthritis Drug Accelerates Arthritis, “Miracle” Alzheimer’s Drug Earns “Accelerated Approval”

By [Ben Bartee](#)

Global Research, January 13, 2023

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the **Translate Website** button below the author’s name.

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

Among the many lessons that we should have collectively learned as a society in the post-COVID era is that the pharmaceutical industry willfully [lies, manipulates, bribes, and threatens the American public](#) for the sake of profit and social control. Often, the products it markets don’t work or have extremely negative side effects or both.

A pair of recent stories further illustrate the point:

- an arthritis drug that actually exacerbates arthritis, and
- an Alzheimer’s drug rushed through clinical trials that costs more than most people’s annual salaries yet doesn’t actually do much of anything to improve the disease trajectory

The arthritis drug that worsens arthritis

Via [SciTech Daily](#):

“Two recent studies have shown that corticosteroid injections, which are commonly used to treat the pain associated with knee osteoarthritis, may actually contribute to the progression of the disease...

Statistical analysis showed that **corticosteroid knee injections were significantly associated with the overall progression of osteoarthritis in the knee**, specifically in the lateral meniscus, lateral cartilage, and medial cartilage.”

Literal sugar pills – placebos – would be preferable to this. They might not deliver any actual physiological benefit ([although they often confer psychological benefit via the “placebo effect”](#)), but at least they don’t actively worsen the patient’s condition.

\$56k/year Alzheimer's drug

If you monitor the medical industry with a healthy skepticism, you may recall the unprecedented fanfare over a new “miracle” Alzheimer’s drug aducanumab (sold under the brand name “Aduhelm”), which earned “accelerated approval” by the US Food and Drug Administration.

“Accelerated approval” in the context of drug rollout is an immediate red flag. It almost always means that corners were cut and standard safety and efficacy clinical research was not sufficiently performed.

Via [Bangkok Post](#):

“Aduhelm received “accelerated approval” from the FDA in June **despite the fact that an independent panel advising the US drug regulator had found insufficient evidence of its benefit** and some experts had raised concerns about inconsistency in the drug’s clinical data.

At least **three of the 11-member independent committee** that voted unanimously against recommending the drug to the FDA **subsequently resigned.**”

The parallels to the COVID vaxx rollout are startling.

In September 2021, two leading FDA officials resigned over the Biden administration’s unscientific booster recommendations.

Via [Insider](#):

“The US Food and Drug Administration announced the resignations of two top vaccine officials on Tuesday, and reports said the two were leaving in anger over the Biden administration’s plan to roll out COVID-19 booster shots before officials had a chance to approve it.”

While this might seem like welcome news because it illustrates that there are still some honest people in government, the ultimate outcome is that the decent people are all driven out of positions of authority to be replaced by industry yes-men willing to greenlight any pharma product no matter how scant the evidence to support it.

Similar to the [COVID vaxx clinical trial fraud](#), there were significant problems with the original trials that should have warranted further investigation before approval for public use.

Via [New York Times](#):

“Two months before the Food and Drug Administration’s deadline to decide whether to approve [Biogen’s controversial Alzheimer’s drug](#), aducanumab, a council of senior agency officials resoundingly agreed that there wasn’t enough evidence it worked...

On June 7, the F.D.A. [greenlighted the drug](#) anyway — a decision that has been met with [scathing rebuke](#) from many Alzheimer’s experts and other scientists and calls for investigations into how the agency approved a treatment that has little evidence it

helps patients.”

In the end, patient health be damned, the right hands got greased at the FDA, the right officials were made promises of lucrative positions in private industry after departing public service (the infamous revolving door), and voila!

An expensive, ineffective drug gets pushed on vulnerable patients with wildly unrealistic promises of recovery if they just open their hearts and wallets to the good people at Biogen. Their bank accounts get drained while their health further deteriorates.

*

Of course, describing the above as “failures” of modern medicine is largely a subjective judgment based on perspective.

If you’re a patient with one of these conditions, they are, indeed, abject failures that waste your money and keep you preoccupied with non-effective treatments when you could be doing something proactive.

But if you’re an executive at one of the pharmaceutical firms profiting off of human desperation, they’re a whopping success. Not only do they generate massive revenue - they keep patients hopeless, sick, and grasping at straws for the next round of bogus drugs to sell them.

*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

This article was originally published on [The Daily Bell](#).

Ben Bartee is an independent Bangkok-based American journalist with opposable thumbs. Follow his stuff via [Armageddon Prose](#) and/or [Substack](#), [Patreon](#), [Gab](#), and [Twitter](#). He is a regular contributor to Global Research.

Featured image is from TDB

The original source of this article is Global Research
Copyright © [Ben Bartee](#), Global Research, 2023

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Ben Bartee](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will

not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca